Geroscience interventions
Drugs, compounds and therapeutic strategies intended to alter ageing biology.
Find the question you want to explore
Follow a candidate from its biological rationale to human studies and registered trials. An intervention may be promising in cells or animals without being established as safe or effective in people.
29 topic dossiers connect research, trials, universities, funding and patent activity. Coverage is still growing; numbers describe the indexed records, not all evidence worldwide.
Rapamycin
Research concerning mTOR inhibition, rapalogs, ageing biology, and human translation.
Open evidence dossier →Senolytics
Compounds and strategies intended to target senescent cells.
Open evidence dossier →Metformin
Human and preclinical research connecting metformin with ageing-related outcomes.
Open evidence dossier →GLP-1 therapies
Research on GLP-1 receptor agonists and ageing-related health outcomes.
Open evidence dossier →Plasma exchange
Research involving plasma exchange, plasma dilution, and ageing-related outcomes.
Open evidence dossier →NAD metabolism
NAD biology and precursors such as nicotinamide riboside and NMN.
Open evidence dossier →Sirtuins
SIRT-family enzymes, metabolic regulation, stress responses, and longevity.
Open evidence dossier →Spermidine
Evidence on spermidine, autophagy, cardiovascular ageing, and cognition.
Open evidence dossier →Urolithin A
Urolithin A, mitophagy, muscle function, and age-related decline.
Open evidence dossier →Taurine
Taurine levels, supplementation, ageing biology, and health outcomes.
Open evidence dossier →Glycine and GlyNAC
Glycine, GlyNAC, glutathione biology, and metabolic health.
Open evidence dossier →Alpha-ketoglutarate
Alpha-ketoglutarate metabolism and supplementation in ageing.
Open evidence dossier →Acarbose
Glucose metabolism, lifespan studies, and translation to healthy ageing.
Open evidence dossier →Canagliflozin and SGLT2
SGLT2-inhibitor research connected with ageing and organ health.
Open evidence dossier →17α-estradiol
Preclinical longevity research and sex-specific effects.
Open evidence dossier →Young blood and parabiosis
Heterochronic parabiosis, circulating factors, and young-plasma claims.
Open evidence dossier →Fisetin
Preclinical and human research on fisetin as a possible senotherapeutic.
Open evidence dossier →Dasatinib and quercetin
Evidence on the D+Q combination as an experimental senolytic strategy.
Open evidence dossier →Resveratrol
Human and preclinical research on resveratrol, metabolism and healthy ageing.
Open evidence dossier →Anti-inflammatory gerotherapy
Interventions aimed at chronic age-related inflammation rather than one acute disease.
Open evidence dossier →Autophagy enhancers
Compounds and strategies intended to increase cellular recycling in ageing.
Open evidence dossier →Mitochondrial-targeted therapies
Drugs and delivery strategies designed to improve mitochondrial function with age.
Open evidence dossier →AGE cross-link breakers
Experimental approaches to break or prevent advanced-glycation cross-links.
Open evidence dossier →Klotho therapies
Research on Klotho protein, pathway modulation and therapeutic delivery.
Open evidence dossier →Myostatin inhibition
Blocking myostatin to preserve muscle mass and function in later life.
Open evidence dossier →Immune rejuvenation
Strategies intended to restore immune function or immune diversity with age.
Open evidence dossier →CAR-T targeting senescent cells
Engineered immune-cell approaches to recognize and remove senescent cells.
Open evidence dossier →Peptide geroprotectors
Peptides proposed to influence repair, metabolism or age-related decline.
Open evidence dossier →Combination gerotherapies
Multi-target intervention combinations studied against several ageing mechanisms.
Open evidence dossier →